Who are Cipterbin Combined With Vinorelbine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cipterbin-combined-with-vinorelbine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cipterbin Combined With Vinorelbine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cipterbin Combined With Vinorelbine (Cipterbin Combined With Vinorelbine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor combined with vinca alkaloid. Area: Oncology.

marketed Tyrosine kinase inhibitor combined with vinca alkaloid Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cipterbin Combined With Vinorelbine (Cipterbin Combined With Vinorelbine) — Zhejiang Cancer Hospital. Cipterbin combined with vinorelbine uses a dual approach: cipterbin inhibits tumor cell signaling while vinorelbine disrupts microtubule dynamics to arrest cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cipterbin Combined With Vinorelbine TARGET	Cipterbin Combined With Vinorelbine	Zhejiang Cancer Hospital	marketed	Tyrosine kinase inhibitor combined with vinca alkaloid	Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor combined with vinca alkaloid class)

Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cipterbin Combined With Vinorelbine — Competitive Intelligence Brief. https://druglandscape.com/ci/cipterbin-combined-with-vinorelbine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab